Patents Represented by Attorney, Agent or Law Firm George E. Heibel
  • Controlled release formulation
    Patent number: 6673369
    Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: January 6, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashok Rampal, Rajeev S. Raghuvanshi, Manoj Kumar
  • Azole compounds as therapeutic agents for fungal infections
    Patent number: 6670363
    Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: December 30, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashwani Kumar Verma, Sudershan K. Arora, Jasbir Singh Arora, Ashok Rattan
  • Derivatives of monosaccharides as cell adhesion inhibitors
    Patent number: 6590085
    Abstract: This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 8, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Sudershan K Arora, Nawal Kishore, Jang Bahadur Gupta, Vishwas D Joshi
  • Extended release formulation of etodolac
    Patent number: 6586005
    Abstract: A sustained release formulation of etodolac for once daily administration is described.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: July 1, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Rajeev S. Raghuvanshi, Ashok Rampal, Himadri Sen